American Association for Cancer Research
Browse

sorry, we can't preview this file

23266066cir150298-sup-158974_1_supp_3380798_63c36h.docx (217.08 kB)

Supplemental Tables 1 through 4 and Supplemental Figures 1 and 2 from Pretreatment Immune Status Correlates with Progression-Free Survival in Chemotherapy-Treated Metastatic Colorectal Cancer Patients

Download (217.08 kB)
journal contribution
posted on 2023-04-03, 23:07 authored by Kohei Tada, Shigehisa Kitano, Hirokazu Shoji, Takashi Nishimura, Yasuhiro Shimada, Kengo Nagashima, Kazunori Aoki, Nobuyoshi Hiraoka, Yoshitaka Honma, Satoru Iwasa, Natsuko Okita, Atsuo Takashima, Ken Kato, Yasuhide Yamada, Naoyuki Katayama, Narikazu Boku, Yuji Heike, Tetsuya Hamaguchi

Supplemental Table 1 Combined assessment of quantities of two values from among M-MDSC, CD4+ TEM, and CD8+ TEM cells for correlation with PFS Supplemental Table 2 Comparison of patient characteristics between Group 1/2 and Group 3/4 Supplemental Table 3 Univariate analysis of the covariates patient characteristics and cytokines for PFS Supplemental Table 4 Comparisons of 10 cytokine concentrations in plasma between Group 1/2 and Group 3/4 Supplemental Figure 1 (A) Gating strategy and representative dot plots for G-MDSCs, DC (B) Gating strategy and representative dot plots for Treg, NK, Granzyme B+, Perforin+ and Ki-67+ cells Supplemental Figure 2 (A) Change in each immune cell type over time (B) Kaplan-Meier curves for PFS of patients who showed an increase or decrease in immune cells

Funding

JSPS

Ministry of Health, Labour and Welfare, Japan

National Cancer Center

History

ARTICLE ABSTRACT

It remains unclear whether the immunologic status of cells in peripheral blood can be used as a prognostic indicator of response to treatment for patients with unresectable metastatic colorectal cancer (MCRC). We therefore investigated the relationship between the pretreatment immunologic status of 40 patients with MCRC who planned to receive the first-line chemotherapy and their progression-free survival. Twenty-five immune cell subsets, including monocytic myeloid-derived suppressor cells (M-MDSC) and effector memory T cells (TEM), were measured by multicolor-flow cytometry. We divided patients into high and low (above and below the median, respectively) groups based on the median value for each immune cell subset and compared progression-free survival of the two groups. Patients with high M-MDSC, low CD4+ TEM, or low CD8+ TEM quantities had significantly shorter progression-free survival (P = 0.004, 0.005, and 0.002, respectively). Patients were classified into two prognostic groups based on numbers of adverse factors; having two or three adverse factors (n = 21, 52.5%) was correlated with significantly shorter progression-free survival compared with none or one (n = 19, 47.5%; P < 0.001). The presence of two or three adverse factors was an independent poor prognostic factor for progression-free survival (HR, 9.2; 95% confidence interval, 2.5–34.2; P < 0.001). These results provide evidence that pretreatment peripheral immune status can inform the outcome of patients with MCRC treated with first-line chemotherapy. Cancer Immunol Res; 4(7); 592–9. ©2016 AACR.

Usage metrics

    Cancer Immunology Research

    Licence

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC